On October 10, 2022 Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, reported that it has entered into an agreement with CSPC NBP Pharmaceuticals Co., Ltd. (NBP Pharma), a wholly-owned subsidiary of CSPC Pharmaceutical Group Limited (CSPC), to transfer the exclusive rights to develop, manufacture and commercialize batoclimab (HBM9161) in Greater China (including mainland China, Hong Kong, Macau and Taiwan) to NBP Pharma (Press release, Harbour BioMed, OCT 10, 2022, View Source [SID1234621944]). According to the agreement, Harbour BioMed will potentially receive a total of over RMB 1 billion, including an upfront payment of RMB 150 million and other potential milestone payments. In addition, the Company will receive tiered royalties based on annual net sales of batoclimab in Greater China.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Batoclimab is the first novel fully human anti-FcRn monoclonal antibody being developed in Greater China. It blocks FcRn-IgG interactions, accelerating the degradation of autoantibodies and leads to the treatment of pathogenic IgG-mediated autoimmune diseases. As the clinically most advanced FcRn inhibitor being developed in Greater China, batoclimab has the potential to be a breakthrough treatment for a wide spectrum of autoimmune diseases in Greater China. Batoclimab is currently undergoing a number of clinical studies in Greater China including myasthenia gravis (MG), immune thrombocytopenia (ITP), neuromyelitis optical spectrum disorder (NMOSD), Thyroid Eye Disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and pemphigus vulgaris (PV).
Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, said: " Over the past few years, we are delighted to see the excellent clinical efficacy of batoclimab, and are also looking forward to the commercialization of this product. CSPC has a leading position in the commercialization of innovative drug products in China, and we are delighted to enter into this cooperation with CSPC to optimize market potential and advance clinical development, so as to further maximize the value of batoclimab in Greater China. In the future, Harbour BioMed will continue to implement the Company’s strategy, optimize resources, cultivate its innovative R&D capabilities, and leverage the value of its core platforms to develop more differentiated therapies for patients around the world."
"We are pleased to have reached this agreement with Harbour BioMed," said Cuilong Zhang, CEO of CSPC. "Batoclimab is a promising innovative drug, and we hope to accelerate its clinical development, manufacturing, registration and commercialization in China, so as to benefit the patients in China better and earlier